Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
MGC026
Cancer
MacroGenics
P1
C
(36)
Moma-313
Cancer
MOMA Therapeutics
P1
C
(36)
Moma-341
Cancer
MOMA Therapeutics
P1
C
(36)
Mrtx0902
Cancer
Mirati Therapeutics Inc.
P1
C
(36)
Mrtx1133
Cancer
Mirati Therapeutics Inc.
P1
C
(36)
Msk-Tcr5
Cancer
Memorial Sloan Kettering Cancer Center
P1
C
(36)
N-(2-chloro-3-((3,4-dihydro-2H-pyrimido[1,2-c] quinazolin-10- yl)oxy) phenyl)propane-1-sulfonamide hydrochloride
Cancer
ABM Therapeutics Shanghai Company Limited
P1
C
(36)
nb004 tablets
Cancer
Ningbo Newbay Technology Development Co., Ltd
P1
C
(36)
Nbl-028
Cancer
NovaRock Biotherapeutics, Ltd
P1
C
(36)
nd-003 tablets
Cancer
Shenzhen NewDEL Biotech, Co., Ltd
P1
C
(36)
Nei-01
Cancer
New Epsilon Innovation Limited
P1
C
(36)
nkt3447
Cancer
NiKang Therapeutics, Inc.
P1
C
(36)
nkt3964
Cancer
NiKang Therapeutics, Inc.
P1
C
(36)
Nuv-868
Cancer
Nuvation Bio Inc.
P1
C
(36)
nwy001
Cancer
Chipscreen Biosciences, Ltd.
P1
C
(36)
nxp800
Cancer
Nuvectis Pharma, Inc.
P1
C
(36)
nxp900
Cancer
Nuvectis Pharma, Inc.
P1
C
(36)
Omtx705
Cancer
Oncomatryx Biopharma S.L.
P1
C
(36)
Onc-841
Cancer
OncoC4, Inc.
P1
C
(36)
pb101
Cancer
Panolos Bioscience
P1
C
(36)
PD-L1 CAR-T cells
Cancer
Sichuan University
P1
C
(36)
Peel-224
Cancer
Peel Therapeutics Inc
P1
C
(36)
pep07
Cancer
PharmaEngine
P1
C
(36)
pep08
Cancer
PharmaEngine
P1
C
(36)
Phn-010
Cancer
Pheon Therapeutics
P1
C
(36)
Showing 401 to 425 of 534 assets
Previous
Page 17 of 22
Next
